Abcam, ab92698, Anti-SMAD1 + SMAD5 + SMAD9 (phospho S463 + S465 + S467) antibody [MMC-1-104-3]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal SMAD1 + SMAD5 + SMAD9 phospho S463 + S465 + S467 antibody. Suitable for IHC-P, Dot, WB and reacts with Mouse, Rat, Human, Synthetic peptide samples. Cited in 47 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:MMC-1-104-3,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, WB, DotSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody may cross-react with Smad1 Phospho (pS463/465) and Smad9 Phospho (pS465/467).Stimulation may be required to allow detection of the phosphorylated protein.  Please see images below for recommended treatment conditions and positive controls.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Stable for 12 months at -20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Smad1 SMAD5 and SMAD9 proteins sometimes known as receptor-regulated SMADs (R-SMADs) play significant roles in cellular signaling. These proteins act as intracellular mediators for the transforming growth factor-beta (TGF-β) superfamily of cytokines particularly the bone morphogenetic proteins (BMPs). These proteins are expressed in various tissues including bone heart lung and brain where they facilitate specific receptor signaling. These SMAD proteins typically have molecular masses ranging from about 50 kDa to 60 kDa which varies depending on specific post-translational modifications such as phosphorylation.
Biological function summary
The Smad1 SMAD5 and SMAD9 proteins are transcription factors involved in the regulation of gene expression. Upon activation by BMP receptors these proteins undergo phosphorylation then form complexes with SMAD4 another member of the SMAD family. This heteromeric complex translocates into the nucleus where it influences the expression of genes associated with cell proliferation differentiation and apoptosis. The Smad1 SMAD5 and SMAD9 proteins therefore coordinate diverse cellular processes by modulating transcriptional responses to extracellular signals in developmental and homeostatic contexts.
Pathways
Smad1 SMAD5 and SMAD9 proteins integrate into the BMP signaling pathway which is fundamental in bone and cartilage development. These proteins interact closely with BMP type I receptors through phosphorylation-mediated mechanisms. Another pathway involving these SMAD proteins is the TGF-β pathway where their activity converges with other signaling molecules like SMAD2 and SMAD3 resulting in complex regulatory outcomes in cellular contexts. The interactions within these pathways help mediate processes like embryogenesis and tissue homeostasis illustrating the interplay of cell signaling and transcriptional regulation.
Smad1 SMAD5 and SMAD9 proteins associate with conditions like pulmonary hypertension and cancer. Dysregulation within the BMP signaling pathway mediated by improper functioning of these R-SMADs links to abnormal vascular remodeling and cancerous cell growth due to altered proliferative signaling. Additionally Smad1 and SMAD5 show connections with proteins such as BMPR2 in the context of pulmonary arterial hypertension further emphasizing their role as mediators of disease-related signaling pathways. Addressing these proteins' malfunction provides potential therapeutic intervention points for complex pathological states.